Value
3.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 3.0 |
- ▸Expensive valuation
TERN · Why this verdict
Why Terns Pharmaceuticals (TERN) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.7/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company's entire clinical and commercial value rests on TERN-701 as its sole pipeline candidate, meaning any setback to that program eliminates the investment thesis with no offsetting assets. Bear case | Pipeline diversification news or a second program advancing to clinical stage within 12 months would reduce concentration risk. | →Stable |
| CounterA focused single-asset strategy can accelerate development timelines and reduce capital diffusion, and the program may already be de-risked by prior data. | ||
With the stock trading at $52.95 above its $51.92 take-profit and a reward-to-risk ratio of -6.33x, the asymmetry is deeply unfavorable and the engine has flagged a hard exit signal. Targets | Price would need to pull back below $45 to restore a favorable entry with at least 1.5x upside-to-downside ratio. | →Stable |
| CounterShort-term momentum is strong with RSI at 76 and rising OBV, suggesting the market may continue to push the stock higher before a reversal. | ||
The quality score of 1.6 is far below the 4.0 minimum threshold, driven by zero free cash flow, zero return on equity, and zero return on assets, indicating the business is burning cash with no current profitability. Quality | At least one profitability metric — FCF margin or operating margin — turning positive over the next 12 months would signal the quality floor concern is easing. | →Stable |
| CounterBiotech companies routinely run at a loss during clinical-stage operations, and the current ratio of 5x suggests ample liquidity to fund operations. | ||
Despite negative fundamentals, Terns has beaten consensus EPS estimates in 3 of the last 3 reported quarters with an average positive surprise of 10.5%, suggesting the company is managing its cash burn more tightly than analysts expect. Earnings | Continued EPS beats with positive surprise percentage above 5% in the next 2 quarters would validate that management is controlling its burn rate. | →Stable |
| CounterAll beats are on negative EPS estimates — beating a -$0.28 estimate by reporting -$0.24 does not indicate operational progress toward profitability. | ||
The company's entire clinical and commercial value rests on TERN-701 as its sole pipeline candidate, meaning any setback to that program eliminates the investment thesis with no offsetting assets.
→StableBear case
- Expectation
- Pipeline diversification news or a second program advancing to clinical stage within 12 months would reduce concentration risk.
CounterA focused single-asset strategy can accelerate development timelines and reduce capital diffusion, and the program may already be de-risked by prior data.
With the stock trading at $52.95 above its $51.92 take-profit and a reward-to-risk ratio of -6.33x, the asymmetry is deeply unfavorable and the engine has flagged a hard exit signal.
→StableTargets
- Expectation
- Price would need to pull back below $45 to restore a favorable entry with at least 1.5x upside-to-downside ratio.
CounterShort-term momentum is strong with RSI at 76 and rising OBV, suggesting the market may continue to push the stock higher before a reversal.
The quality score of 1.6 is far below the 4.0 minimum threshold, driven by zero free cash flow, zero return on equity, and zero return on assets, indicating the business is burning cash with no current profitability.
→StableQuality
- Expectation
- At least one profitability metric — FCF margin or operating margin — turning positive over the next 12 months would signal the quality floor concern is easing.
CounterBiotech companies routinely run at a loss during clinical-stage operations, and the current ratio of 5x suggests ample liquidity to fund operations.
Despite negative fundamentals, Terns has beaten consensus EPS estimates in 3 of the last 3 reported quarters with an average positive surprise of 10.5%, suggesting the company is managing its cash burn more tightly than analysts expect.
→StableEarnings
- Expectation
- Continued EPS beats with positive surprise percentage above 5% in the next 2 quarters would validate that management is controlling its burn rate.
CounterAll beats are on negative EPS estimates — beating a -$0.28 estimate by reporting -$0.24 does not indicate operational progress toward profitability.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Terns Pharmaceuticals carries a pipeline concentrated in a single program, with the stock already trading above its resistance-based take-profit level and a strongly negative reward-to-risk ratio of -6.33x, making the current entry unattractive despite a solid earnings beat streak and high implied-volatility premium.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.2 |
| MACD | 0.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 3.4 |
- ▸Overbought (RSI 76)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
5.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 5.0 |
Insider
5.0/10data confidence 50%Peer rank
6.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 7.4 |
| growth rank | 5.0 |
- ▸Conservative debt levels
Technical
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.9 |
| support resistance | 0.5 |
| 52w position | 9.9 |
Risk (lower is worse)
8.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.5 |
| days to cover | 10.0 |
| volatility | 10.0 |
| put call | 10.0 |
| implied vol | 5.6 |
| debt equity | 9.6 |
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
8.9/10data confidence 50%| Component | Sub-score |
|---|---|
| earnings history | 10.0 |
| surprise avg | 7.8 |
- ▸Strong earnings: 3B/0M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- MOMENTUM:5.3>=4.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-1.0=NEGATIVE
Warning (2)
- MOMENTUM:5.3<5.5 (soft — BUY_NOW allowed but watch)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-0.99
Upside
-14.9%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Catalyst at 8.9 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:-1.0=NEGATIVE.
The strongest dimensions are Catalyst at 8.9, Risk (lower is worse) at 8.6, and Peer rank at 6.7; the weakest are Quality at 1.6, Value at 3.0, and Technical at 4.1. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of -0.99 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Single Asset Pipeline Risk
Trip ifStock price drops below $40, more than 25% below the current $52.95, on a pipeline setback or clinical failure announcement for TERN-701.
- P2Negative Reward Risk Ratio
Trip ifPrice rises above $60, exceeding the current resistance by more than 13%, without a corresponding improvement in the asymmetry ratio above 1.5.
- P3Quality Below Minimum Floor
Trip ifFCF margin falls below -20% of revenue in any reported quarter, indicating the cash burn rate is accelerating beyond current levels.
- P4Earnings Beat Streak Resilience
Trip ifEPS surprise falls below 0% in at least 2 of the next 3 reported quarters, breaking the current beat streak.